Merck & Company (MRK) Shares are Up 8.86%

Merck & Company (MRK) : Traders are bullish on Merck & Company (MRK) as it has outperformed the S&P 500 by a wide margin of 4.99% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 8.4%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 8.86% in the last 1 week, and is up 7.6% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.

Merck & Company (NYSE:MRK): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $62.51 and $60.74 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $64.00. The buying momentum continued till the end and the stock did not give up its gains. It closed at $63.86, notching a gain of 10.41% for the day. The total traded volume was 72,875,999 . The stock had closed at $57.84 on the previous day.

The stock has recorded a 20-day Moving Average of 8.58% and the 50-Day Moving Average is 11.01%. Merck & Co., Inc. is up 20.11% in the last 3-month period. Year-to-Date the stock performance stands at 22.95%.

Merck & Company (MRK) stock is expected to deviate a maximum of $7.44 from the average target price of $62.67 for the short term period. 12 Street Experts have initiated coverage on the stock with the most promising target being $80 and the most muted being $53.


Merck & Co., Inc. is a global health care company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. The Companys Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures. Human health pharmaceutical products consist of therapeutic and preventive agents, generally sold by prescription, for the treatment of human disorders. The Company sells these human health pharmaceutical products primarily to drug wholesalers and retailers, hospitals, government agencies and managed health care providers. The Animal Health segment discovers, develops, manufactures and markets animal health products, including vaccines. The Companys animal health products are sold to veterinarians, distributors and animal producers.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.